iTeos Therapeutics, Inc. — Net Income by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/8ac6db57-9275-4cb2-9482-eba12ba04ad8/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-134.4M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-033066 |
| FY 2023 | $-112.6M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-026866 |
| FY 2022 | $96.7M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-020071 |
| FY 2021 | $214.5M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-009668 |
| FY 2020 | $-38.0M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-015146 |
| FY 2019 | $-22.5M | 2019-01-01 – 2019-12-31 | evidence 0001564590-21-015146 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
iTeos Therapeutics, Inc. — all facts · Revenue · Operating Income